Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.47 |
| ▸ | NAMPT | P43490 | 4/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21229063 | 0.88 | NAMPT (0.45) | HDAC1HDAC3HDAC6NAMPTHDAC2 | |
| SCHEMBL21229053 | 0.88 | HDAC1 (0.51) | HDAC1HDAC3HDAC6NAMPTHDAC2 | |
| SCHEMBL21229129 | 0.87 | NAMPT (0.44) | HDAC1HDAC3HDAC6NAMPTHDAC2 | |
| SCHEMBL21229087 | 0.87 | PTPN11 (0.46) | HDAC1HDAC3HDAC6NAMPTHDAC2 | |
| SCHEMBL21229077 | 0.85 | HDAC1 (0.45) | HDAC1HDAC3HDAC6NAMPTHDAC2 | |
| SCHEMBL21229056 | 0.84 | NAMPT (0.38) | HDAC1HDAC3HDAC6NAMPTHDAC2 | |
| SCHEMBL21229107 | 0.83 | HDAC1 (0.43) | HDAC1HDAC3HDAC6NAMPTHDAC2 | |
| SCHEMBL21229130 | 0.83 | CSNK2A2 (0.52) | HDAC1HDAC3HDAC6HDAC2HDAC8 | |
| SCHEMBL21229041 | 0.83 | EGLN1 (0.44) | HDAC1HDAC3HDAC6NAMPT | |
| SCHEMBL21229137 | 0.82 | XDH (0.49) | HDAC1NAMPTHDAC2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377748-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2019-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377748-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | HDAC1 2819/4885HDAC3 2399/4885HDAC6 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.